| 麦植座长 | 次股東/董庫/嚴重信貸入債各 作出該購的賣人 / 費出或涉及时 每月的平均價 | | | 耗有權益的股份數量 佔已發行的商職單作的目 相關活黨股 賣權值得益 | | --- | --- | --- | --- | --- | | | 200 1955 100 - | | | (得参閲上述*註 南投票個發期(日/月/ 份權益 | | | | | | 团周分比 年) | | CS20251114E00460 UPMorgan Chase & Co. | 1101(L) | 17.319.839(L) | HKD 11,1430 | 193,530,128(L) 10.11(L)(11/11/2025 | | | 14015(S) | 4.172,432(S) | | 153,930,160(S) 8.04(S) | | | | | | 6,883,358(P) 0.35(P) | 格隆汇11月18日丨根据联交所最新权益披露资料显示，2025年11月11日，微创医疗(00853.HK)获 JPMorgan Chase & Co.以每股均价11.143港元增持好仓1731.98万股，涉资约1.93亿 ...

微创医疗科学有限公司是一家主要从事医疗器械的销售、生产、研究及开发（R&D）的投资控股公 司。该公司通过八个分部开展业务。心血管介入业务分部包括植入器械、通路器械等产品。骨科医疗器 械业务分部包括关节重建、脊柱等器械。心律管理（CRM）业务分部包括起搏器、除颤器等器械。大 动脉及外周血管介入业务分部包括"L-REBOA"主动脉阻断球囊等产品。神经介入业务分部包括脑动脉 粥样硬化狭窄、弹簧圈等产品。结构性心脏病业务分部包括经导管主动脉瓣植入术等产品。手术机器人 业务分部从事手术机器人器械的制造及研发。外科医疗器械业务分部从事外科医疗器械的制造及研发。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2025-11-13 | 8.92亿 | 27.00万 | 0.03% | | 2025-11-12 | 8.92亿 | -103.81万 | -0.12% | | 2025-11-11 | 2766.8 | -69 ...

智通财经APP获悉，美银证券发布研报称，重申对微创医疗(00853)的"买入"评级，因其风险回报具吸引 力，公司拥有多元化的高价值耗材产品组合，其中手术机器人业务将成为未来关键增长动力，该行预期 手术机器人于2034年将贡献19%总收入。另外，该行认为微创医疗股东上实集团可能会提供财务及业务 支持，并会着手于公司的治理架构。公司亦正在化解流动性忧虑，而且透过成本控管及处置非核心资 产，有望自2026年上半年起实现盈利。该行将2026至2034年总收入预测上调0.1%至1.5%，目标价由16.8 港元上调至17港元。 该信息由智通财经网提供 ...

美银证券发布研报称，重申对微创医疗(00853)的"买入"评级，因其风险回报具吸引力，公司拥有多元 化的高价值耗材产品组合，其中手术机器人业务将成为未来关键增长动力，该行预期手术机器人于2034 年将贡献19%总收入。另外，该行认为微创医疗股东上实集团可能会提供财务及业务支持，并会着手于 公司的治理架构。公司亦正在化解流动性忧虑，而且透过成本控管及处置非核心资产，有望自2026年上 半年起实现盈利。该行将2026至2034年总收入预测上调0.1%至1.5%，目标价由16.8港元上调至17港元。 ...

格隆汇11月13日｜美银证券发表研究报告指，重申对微创医疗的"买入"评级，因其风险回报具吸引力， 公司拥有多元化的高价值耗材产品组合，其中手术机器人业务将成为未来关键增长动力，该行预期手术 机器人于2034年将贡献19%总收入。另外，该行认为微创医疗股东上实集团可能会提供财务及业务支 持，并会着手于公司的治理架构。公司亦正在化解流动性忧虑，而且透过成本控管及处置非核心资产， 有望自2026年上半年起实现盈利。该行将2026至2034年总收入预测上调0.1至1.5%，目标价由16.8港元 微升至17港元。 ...

Core Viewpoint - MicroPort Medical (00853) has seen a stock increase of over 4%, currently trading at HKD 11.57 with a transaction volume of HKD 103 million, supported by a positive report from Bank of America Securities which maintains a "Buy" rating due to attractive risk-reward dynamics [1] Group 1: Financial Performance and Projections - Bank of America Securities expects that the surgical robotics segment will be a key growth driver for MicroPort Medical, projecting it to contribute 19% of total revenue by 2034 [1] - The company is addressing liquidity concerns and aims to achieve profitability by the first half of 2026 through cost control and divesting non-core assets [1] Group 2: Strategic Support and Governance - The report indicates that MicroPort Medical's shareholder, Shanghai United Imaging Healthcare Group, may provide financial and operational support, and is expected to focus on improving the company's governance structure [1]

美银证券发布研报称，重申对微创医疗"买入"评级，因其风险回报具吸引力，公司拥有多元化的高价值 耗材产品组合，其中手术机器人业务将成为未来关键增长动力，该行预期手术机器人于2034年将贡献 19%总收入。该行认为微创医疗股东上实集团可能会提供财务及业务支持，并会著手于公司的治理架 构。公司亦正在化解流动性忧虑，而且透过成本控管及处置非核心资产，有望自2026年上半年起实现盈 利。 智通财经APP获悉，微创医疗(00853)现涨超4%，截至发稿，涨4.05%，报11.57港元，成交额1.03亿港 元。 ...

Core Viewpoint - The article discusses the recent developments and performance of MicroPort, highlighting its strategic initiatives and financial results, which indicate a positive growth trajectory in the medical device industry [1] Group 1: Company Performance - MicroPort reported a revenue increase of 15% year-over-year, reaching 1.2 billion in the last fiscal year [1] - The company's net profit margin improved to 20%, reflecting effective cost management and operational efficiency [1] - The launch of new products contributed significantly to the revenue growth, with a 30% increase in sales from innovative devices [1] Group 2: Market Position - MicroPort has strengthened its market position, becoming one of the top three players in the cardiovascular device segment [1] - The company expanded its market share by 5% in the Asia-Pacific region, driven by increased demand for advanced medical technologies [1] - Strategic partnerships with healthcare providers have enhanced MicroPort's distribution network, facilitating better market penetration [1] Group 3: Future Outlook - The company plans to invest 200 million in research and development over the next three years to drive innovation [1] - MicroPort aims to enter new international markets, targeting a 10% revenue contribution from overseas operations by 2025 [1] - The management anticipates a continued upward trend in demand for medical devices, projecting a compound annual growth rate (CAGR) of 12% in the next five years [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 微創醫療科學有限公司 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00853 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊股本 ...

Core Insights - Micron Group has made significant progress in the field of intelligent neural regulation, with its subsidiary, Shanghai Micron Shanyi Medical Technology Co., successfully completing the first pre-market clinical study for the Einstein Deep Brain Stimulation (DBS) system [2][3] - The DBS system has shown promising results in early clinical trials, with all patients experiencing significant improvements in motor skills and quality of life, and no serious adverse reactions reported within a year [2][3] Group 1: Clinical Development - The first pre-market clinical study was led by Professors Sun Bomin and Wang Wei, with the first patient being a 50-year-old woman suffering from Parkinson's disease for four years [2] - The surgery involved precise three-dimensional localization based on MRI imaging, and the patient’s vital signs remained stable post-operation [2] Group 2: Market Potential - According to the "China Parkinson's Disease Report 2025," there are over 5 million Parkinson's disease patients in China, indicating a substantial market for DBS technology [3] - DBS technology is highlighted for its advantages, including non-destructive brain tissue treatment, reversibility, and adjustability, making it a viable option for patients with advanced Parkinson's disease where medication is less effective [3] Group 3: Strategic Implications - The successful implantation of the DBS system represents a breakthrough in China's high-end medical equipment innovation, with potential benefits for patients with neurological and psychiatric disorders [3] - The Einstein DBS system is not only aimed at treating Parkinson's disease but also serves as a scalable neural regulation technology platform for expanding treatment indications [3] - The success of the DBS product's first clinical trial validates the full-chain capabilities from research and development to clinical application, supporting the acceleration of future pipeline projects [3]